

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 January 2024 (18.01.2024)



(10) International Publication Number
WO 2024/011316 A1

(51) International Patent Classification:

C07D 487/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/519 (2006.01) *A30B 7/00* (2006.01)
A61P 9/00 (2006.01) *C30B 29/54* (2006.01)
A61P 25/08 (2006.01)

(21) International Application Number:

PCT/CA2023/050930

(22) International Filing Date:

11 July 2023 (11.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/368,208 12 July 2022 (12.07.2022) US

(71) Applicant: **THRYV THERAPEUTICS INC.** [CA/CA];

999 De Maisonneuve West Boulevard, Suite 1250, Montreal, Québec H3A 3L4 (CA).

(72) Inventors: **VIDAL, Marc**; 999 De Maisonneuve West Boulevard, Suite 1250, Montreal, Québec H3A 3L4 (CA). **KHALIFA, Maroua**; 999 De Maisonneuve West Boulevard, Suite 1250, Montreal, Québec H3A 3L4 (CA). **WANG, Liyu**; Pharmaron Beijing, o. Ltd. No. 6, TaiHe Road, BDA, Beijing, Beijing 100176 (CN). **DAI, Wenying**; Pharmaron Beijing, o. Ltd. No. 6, TaiHe Road, BDA, Beijing, Beijing 100176 (CN).

(74) Agent: **ROBIC AGENCE PI S.E.C./ROBIC IP AGENCY LP**; 630 Rene-Levesque Boulevard W, 20th Floor, Montreal, Québec H3B 1S6 (CA).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

(54) Title: SALTS OF N-[4-(4-[[2-(DIMETHYLAMINO)ETHYL]AMINO]-3-METHYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL)-2-FLUOROPHENYL]-2,5-DIFLUOROBENZENESULFONAMIDE AND CRYSTALLINE FORMS THEREOF




Figure 29

(57) Abstract: Compound of Formula (II) is provided: (II) A crystalline form of the compound of Formula (II) is provided. The compound of Formula (II), and crystalline form thereof can be used for the treatment of several conditions linked to the inhibition of SGK-I, such as a cardiovascular disease selected from the group consisting of Long QT syndrome, heart failure, arrhythmia such as atrial fibrillation, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure; cancer; epilepsy; Parkinson's disease; and Lafora disease.

[Continued on next page]

WO 2024/011316 A1

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*